Drug combinations as a first line of defense against coronaviruses and other emerging viruses
The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-
equipped for future pandemics. While unprecedented strides have been made developing …
equipped for future pandemics. While unprecedented strides have been made developing …
Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19
HB Rasmussen, R Thomsen… - Pharmacology Research …, 2022 - Wiley Online Library
GS‐441524, the parent nucleoside of remdesivir, has been proposed to be effective against
Covid‐19 based on in vitro studies and studies in animals. However, randomized clinical …
Covid‐19 based on in vitro studies and studies in animals. However, randomized clinical …
Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis
C Sellitto, G Corbi, N Bertini, T Ascione… - Journal of …, 2023 - Taylor & Francis
Remdesivir (RDV) is a broad-spectrum antiviral drug, now approved by Regulatory
Agencies for COVID-19 treatment. RDV is associated with improvements in clinical …
Agencies for COVID-19 treatment. RDV is associated with improvements in clinical …
Risk/benefit profiles of currently approved oral antivirals for treatment of COVID-19: similarities and differences
S Corritori, N Savchuk, CD Pauza - Covid, 2022 - mdpi.com
A complete response to the challenge of COVID-19 requires diagnosis, prevention, and
treatment strategies. Until recently, the treatment arm has included largely ineffective, often …
treatment strategies. Until recently, the treatment arm has included largely ineffective, often …
Telmisartan nanosuspension for inhaled therapy of COVID-19 lung disease and other respiratory infections
Vaccine hesitancy and the occurrence of elusive variants necessitate further treatment
options for coronavirus disease 2019 (COVID-19). Accumulated evidence indicates that …
options for coronavirus disease 2019 (COVID-19). Accumulated evidence indicates that …
DCcov: Repositioning of drugs and drug combinations for SARS-CoV-2 infected lung through constraint-based modeling
Summary The 2019 coronavirus disease (COVID-19) became a worldwide pandemic with
currently no approved effective antiviral drug. Flux balance analysis (FBA) is an efficient …
currently no approved effective antiviral drug. Flux balance analysis (FBA) is an efficient …